Sotyktu (Deucravacitinib)

Sotyktu (Deucravacitinib)

Sotyktu

Deucravacitinib

Tablets: 6 mg

Bristol Myers Squibb

Medical Use

Sotyktu (deucravacitinib) is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Limitations of Use: Sotyktu should not be used in combination with other potent immunosuppressants.

Recommended Dosage:

  • -Pre-Treatment Evaluation: Screen patients for active and latent tuberculosis (TB) infection before starting Sotyktu. If TB is detected, begin appropriate treatment for TB before initiating Sotyktu. Ensure immunizations are up-to-date according to current guidelines.
  • -Dosage: The recommended dose is 6 mg taken orally once daily, with or without food. Do not chew, crush, or split the tablets.
  • -Hepatic Impairment: Sotyktu is not recommended for patients with severe hepatic impairment (Child-Pugh Class C).